

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UMP HEALTHCARE HOLDINGS LIMITED

聯合醫務集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 722)

POSITIVE PROFIT ALERT

This announcement is made by UMP Healthcare Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the Company’s annual report for the financial year ended 30 June 2016 (the “**2016 Annual Report**”), the announcement of the Company dated 15 December 2016 and the circular of the Company dated 8 February 2017 (the “**Circular**”). Terms defined in the 2016 Annual Report and the Circular shall have the same meanings when used in this announcement.

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on the information currently available to the Board and the preliminary review of the unaudited management accounts of the Group, the Board expects that the net profit of the Company for the financial year ended 30 June 2017 (“**FY2017**”) will represent a significant increase of approximately 600% as compared with the net profit of HK\$6.8 million for the financial year ended 30 June 2016 (“**FY2016**”).

Such significant increase in net profit is primarily attributable to the gain of approximately HK\$46.2 million from the Proposed Disposal, which was completed on 23 March 2017. Please refer to the Circular for further details.

Excluding the financial impact of the Proposed Disposal and the PRC Developing Business, the Company’s Adjusted EBITDA* has increased by approximately 10.5% in FY2017. Such increase was due to overall improving operating performance. Based on the preliminary review of the unaudited management accounts of the Group, the Company expects to record a total revenue of approximately HK\$514 million in FY2017, representing a year on year increase of approximately 13%. The Company will provide additional breakdown of financial and operational information in its annual results announcement.

The Company has yet to finalise its results for FY2017. The information contained in this announcement is only based on the preliminary review of the Group's unaudited management accounts with reference to the information currently available to the Board and is not based on any figures or information that has been audited or reviewed by the auditors or the audit committee of the Company. Shareholders and investors are advised to read carefully the annual results announcement of the Company for FY2017, which is expected to be published before the end of September 2017.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By Order of the Board
UMP Healthcare Holdings Limited
SUN Yiu Kwong
Chairman and Chief Executive Officer

Hong Kong, 10 August 2017

As at the date of this announcement, the Board comprises Dr. SUN Yiu Kwong as chairman, chief executive officer and executive director, Ms. KWOK Cheuk Kwan, Jacquen, as managing director and executive director, Mr. TSANG On Yip, Patrick, Dr. SUN Man Kin, Michael and Mr. LEE Kar Chung, Felix as executive directors, and Mr. LEE Luen Wai, John BBS JP, Dr. LI Kwok Tung, Donald SBS JP and Mr. YEUNG Wing Sun, Mike as independent non-executive directors.

* *Adjusted EBITDA is defined as the Company's operating profit before interests, tax, depreciation and amortization excluding (i) the operating losses of PRC corporate healthcare solutions in Beijing and Shanghai, (ii) the operating losses of the clinical healthcare business in Shanghai, (iii) the share of losses of the Beijing joint venture, (iv) equity-settled share option expenses, (v) one-off listing expenses for the financial year ended 30 June 2016 and (vi) the gain from the Proposed Disposal for the financial year ended 30 June 2017.*